Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Rini Describes Hypertension as a Biomarker

July 22nd 2011

Dr. Brian I. Rini from the Taussig Cancer Institute Describes Hypertension as a Biomarker in RCC

Dr. West Explains the Pemetrexed Clinical Trial

July 22nd 2011

Dr. Jack West from Swedish Cancer Institute Explains the Pemetrexed Clinical Trial

Dr. Tsimberidou on the Personalized Medicine Results

July 21st 2011

Dr. Apostolia M. Tsimberidou from MD Anderson Cancer Center on the Personalized Medicine Study Results

Karen Hagemaster on Chemo Documentation Study

July 20th 2011

Karen Hagemaster from Advocate Good Samaritan Hospital on Chemotherapy Documentation Study

Dr. Kris Discusses Driver Mutations Test False Negatives

July 20th 2011

Dr. Mark G. Kris thoracic chair at Memorial Sloan-Kettering Cancer Center Discusses Driver Mutations Test False Negatives

Dr. West on the Gefitinib Advanced NSCLC Trial

July 19th 2011

Dr. Jack West Swedish Cancer Institute on the Gefitinib Advanced non-small cell lung cancer Trial

Dr. Hoos Explains the Future of Immunotherapy

July 18th 2011

Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role

Interim Safety Data Compared in Ixabepilone TITAN Trial

July 18th 2011

Researchers are continuing to explore whether ixabepilone (Ixempra) is a better choice as adjuvant chemotherapy for patients with early-stage, triple-negative breast cancer than the standard paclitaxel (Taxol).

Dr. Whelan Provides a MA.20 Trial Result Summary

July 14th 2011

Dr. Tim J. Whelan from Juravinski Cancer Centre Provides a MA.20 Trial Result Summary

Aiming for Immunity: New Therapies in Sights

July 14th 2011

Even before the FDA approved ipilimumab in March, the field of cancer immunotherapy was a lively area of scientific inquiry.

Dr. Hoos Describes Ipilimumab and Future Immunotherapies

July 13th 2011

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Tim Turnham on the Melanoma Research Foundation

July 12th 2011

Dr. Tim Turnham the executive director of the melanoma research foundation Describes the organization

Dr. Hoos on Tools Available to Measure Ipilimumab's Success

July 7th 2011

Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success

Dr. Schuchter on the Next Steps in Melanoma Research

July 7th 2011

Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research

Dr. Kris Talks About Defining Biomarkers

July 5th 2011

Dr. Mark G. Kris from memorial sloan-kettering Talks About the importance of Defining the broad term Biomarkers

Dr. Hoos Discusses the Clinical Kinetics of Immunotherapy

July 1st 2011

Dr. Axel Hoos the medical lead in Immunology/Oncology at Bristol-Myers Squibb Discusses the Clinical Kinetics of Immunotherapy

Routine Tests and Procedures in Cardiac Patients May Increase Cancer Risk

June 30th 2011

Researchers have reported that acute myocardial infarction (MI) patients who are exposed to low-dose ionizing radiation from imaging and therapeutic procedures may be at increased risk of cancer.

Donna Berry, PhD, RN 2011 ONS Distinguished Researcher Award Winner

June 29th 2011

Nurse scientist Donna Berry, PhD, RN, received the 2011 ONS Distinguished Researcher Award, which recognizes a nurse researcher whose work has enhanced the science and practice of oncology nursing.

Population Stratification and Cancer Risk Assessment: An Interview With Jill Barnholtz-Sloan, PhD

June 28th 2011

Population stratification refers to differences in allele frequencies between cases and controls, resulting from systematic differences in ancestry, as opposed to associations between genes and disease.

4 Questions for Martine Piccart-Gebhart, MD, PhD: Noted Breast Cancer Researcher Has Bright Hopes for HER2 Targets

June 27th 2011

Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.